Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

Parkinson's Disease & Parkinsonism

Clinical Overview: Parkinson's Disease, Parkinsonism, Multiple System Atrophy, and Progressive Supranuclear Palsy

Parkinson's Disease

Parkinson’s disease (PD) is a neurodegenerative disorder characterized primarily by loss of dopamine neurons in the substantia nigra. Symptoms generally develop on one body side slowly over years but the progression may differ from one person to another due to the diversity of the disease. People with PD may experience tremor, mainly at rest (described as pill rolling tremor in hands), bradykinesia, limb rigidity, gait and balance problems. Prevalence is approximately 200 cases per 100,000 population, and the incidence is about 25 cases per 100,000 population, but these figures might show differences from one region of the world to another.

When motor manifestations appear, people with PD have lost more than 50% of nigral dopamine cells suggesting that pathological changes may begin many decades before the appearance of clinical signs. The premotor phase is characterized in many cases by non-motor manifestations such as REM-sleep behavior disorder, apathy, mood changes, anxiety, constipation and loss of olfaction.

View complete description  

The cause of PD is probably multifactorial, with contributions from hereditary predisposition, environmental toxins, and aging. In recent years it has become evident that there is also a genetic contribution to PD and several mutations have been identified (GBA, LRRK2, PRKN, SNCA), although in most world regions only a minority cases are explained by genetics.

Diagnosis remains clinical and is based on motor manifestations. Brain MRI or CT and molecular imaging (ie of the dopamine transporter in the striatum) of the striatum may be performed to support clinical evaluation. The clinical features of PD include both the motor symptoms (described above), as well as non-motor issues. These non-motor symptoms include neuropsychiatric symptoms including mood disturbances and cognitive changes; autonomic dysfunction, pain and sleep issues.   

Levodopa has remained the cornerstone of PD treatment for more than 50 years. However, after a few years of treatment and mainly due to the progression of the disease, the benefit of levodopa shortens and motor complications appear in many patients. This had led to the introduction of many other medications including inhibitors of catechol-O-methyltransferase (COMT), monoamine oxidase type B (MAO-B) inhibitors and dopamine agonists. Enzyme blockers act by either extending levodopa or dopamine half-life while dopamine agonists mimic the action of dopamine on brain dopamine receptors.

More recently, surgical and infusion therapies have become available to improve management in selective patients with motor complications. Surgery includes the use of deep brain stimulation of the subthalamic nucleus and globus pallidus internus. The use of drug infusions is based on the possibility to deliver continuously either levodopa or apomorphine (a dopamine agonist with high affinity to dopamine receptors), mimicking the natural tonic receptor stimulation in the basal ganglia.
 

Parkinsonism

The defining feature of parkinsonism is bradykinesia, or slowness with decrement and degradation of repetitive movements (“fatigue”).  Subtle “bradykinesia” has been reported to occur in the “normal elderly” population, but this may reflect a non-specific slowness rather than bradykinesia as defined above.  Parkinson’s disease is the most common neurodegenerative cause of parkinsonism.  Other causes include multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration. 

These other neurodegenerative conditions are sometimes grouped together under term of “atypical parkinsonism” or “parkinson-plus syndromes”.  They do not respond as well to  dopaminergic treatments and generally have a worse prognosis compared to typical Parkinson’s disease.   Degenerative causes of parkinsonism may be difficult to diagnose in the earliest stages and ancillary investigations may be of limited value in this instance.

Parkinsonism can also be symptomatic, as a result of various vascular, drug-related, infectious, toxic, structural and other known secondary causes. Of these, drug-induced parkinsonism is probably the most common and includes agents that block post-synaptic dopamine D2 receptors with high affinity (such as antipsychotic and anti-emetic medications) and sodium valproate.  Vascular parkinsonism (“arteriosclerotic pseudoparkinsonism”) tends to have a lower body emphasis with gait disturbance and concomitant cognitive impairment.

Contributed by David John Burn, MD, FRCP, Professor, Clinical Ageing Reserach Unit, Campus for Ageing and Vitality, Newcastle University, Newcastle Upon Tyne, UK
 

Multiple System Atrophy (MSA)

July 2019

Multiple system atrophy (MSA) is a rare and progressive α-synucleinopathy associated with oligodendroglial inclusions and neuronal loss affecting the striatum, substantia nigra, pons, and cerebellum among other brain areas. Clinically, symptoms may include severe parkinsonism unresponsive to levodopa, cerebellar ataxia, autonomic or pyramidal dysfunction in variable combination. According to predominance of parkinsonian or cerebellar symptoms patients are classified into subtype MSA-P or MSA-C, respectively. Mean age at motor symptom onset is 56.2 ± 8.4 years with no difference in sex distribution, and median survival is 6 to 10 years (9.8 years). Prior to motor symptom onset 20-75% of patients experience a prodromal phase which lasts from several months to years and is characterized by autonomic failure affecting cardiovascular, respiratory, urogenital, gastrointestinal, and sudomotor functions. In addition, rapid eye movement sleep behavior disorder (RBD) is frequently observed in the premotor stage of α-synucleinopathies with more than half of patients reporting RBD prior to motor onset and is present in up to 88% of patients diagnosed with probable MSA. To date, the etiology of MSA is still elusive, yet a complex interaction incorporating genetic predisposition and environmental factors is suggested to drive disease initiation and progression, as familial aggregation following an autosomal dominant or recessive inheritance pattern has been reported in several European and Japanese families. Nevertheless, MSA is largely considered to occur sporadically.

Currently, treatment options focus on specific signs and symptoms, and include medications to raise blood pressure or to reduce signs of Parkinsonism (transient response rate for 1-3 years in 38%), impotence drugs, bladder care, physiotherapy and speech therapy.

Authored by Gregor Wenning, MD, PhD, Professor of Clinical Neurbiology, Medical University of Innsbruck, Austria
 

Progressive Supranuclear Palsy (PSP)

July 2019

Progressive Supranuclear Palsy (PSP) is an adult-onset neurodegenerative disorder with cerebral four-repeat (4R-) tau pathology in neurons, oligodendrocytes and astrocytes. Neurofibrillary tangles in PSP predominate in the brain stem and basal ganglia and to lesser degree in frontal and temporal cortices and cerebellum. Oligodendroglial coiled bodies are variably present. Tau-positive tufted astrocytes confirm the diagnosis. The differential anatomical distribution of tau pathology appears to determine the highly variable clinical manifestations of PSP.

The predominant clinical manifestation of PSP is called Richardson’s syndrome, i.e. a combination of postural instability with slowing of vertical saccades and supranuclear vertical gaze palsy in the early clinical course. The second most common manifestation is PSP with predominant Parkinsonism, i.e. an akinetic-rigid syndrome developing supranuclear ocular motor dysfunction at a later disease stage.  Other clinical manifestations of PSP include progressive gait freezing, predominant frontal presentation, predominant speech/language disorder, and corticobasal syndrome, among others.

PSP is a sporadic disease, with common variants in MAPT being the most important risk factor. PSP typically shows its first clinical signs and symptoms after the age of 40, with 66 years on average. Average survival time from disease onset to death is 7.9 yrs., with aspiration pneumonia due to bulbar dysphagia being the most common cause. There is no approved drug available for PSP. Recommended off-label medications, physiotherapy and speech therapy provide utmost limited and temporal improvement in motor functions.

Most important unmet needs in PSP research are the characterization of prodromal conditions suggestive of PSP, imaging or fluid biomarkers to objectively diagnose and track the disease, and the development of clinically meaningful disease-modifying therapies.

Authored by Günter Höglinger, MD, Chair, Dept. of Neurology, Hannover Medical School, Hannover, Germany
 

Contributed by Marcelo Merello, MD
Director, Neuroscience Department
Head Movement Disorders Section
Institute for Neurological Research Raul Carrea (FLENI)
Buenos Aires, Argentina

2019 Updates contributed by Angelo Antonini, MD, PhD
Professor, Department of Neuroscience
University of Padua, Italy

 

Jump to: 

Resources     Education     Research tools

Resources: Parkinson's Disease and Parkinsonism

Please wait while we gather your results.

Latest Journal Articles

The latest PD and Parkinsonism research published in Movement Disorders and Movement Disorders: Clinical Practice

Evidence-Based Medicine Reviews

The latest MDS Reviews about treatments for both motor and non-motor symptoms in PD.

Working Groups

MDS convenes a variety of Task Forces addressing mandates and Study Groups advancing the science of PD and Parkinsonisms.

Patient Education

Handouts on movement disorder topics for physicians and patients, translated into multiple languages.

clear all

Resource Type

Areas of Interest subtopics

Please wait while we gather your results.

Latest Articles and Media

Web article

Sex and gender in movement disorders

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Animal Models of Prodromal Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Does glucocerebrosidase activity correlate with disease risk or phenotype severity in Parkinson's disease?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Neuropsychiatric features of punding and hobbyism in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Perampanel may reduce alpha-synuclein transmission in Parkinson's disease. A possible therapeutic target?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)
  • Synucleinopathy

Podcast

Swim for Parkinson: Swimming together to improve together

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Exercise
  • Parkinson's Disease (PD)

Podcast

The most impactful paper related to movement disorders therapy in the 20th century

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Dopaminergic medications
  • Parkinson's Disease (PD)

Web article

Autophagy in Parkinson’s disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Blinded RT-QuIC analysis of alpha-synuclein biomarker in skin tissue from Parkinson's disease patients

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Biomarkers
  • Parkinson's Disease (PD)

Web article

Non-Invasive Brain Stimulation for Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Non-invasive stimulation
  • Parkinson's Disease (PD)

Web article

Istradefylline, Does it Work?

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Can we make a new diagnosis and treat Parkinson’s disease by telemedicine?

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)
  • Telemedicine

Podcast

Acetylcholine nuclei atrophy predicts gait changes in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Gait & Balance Disorders
  • Parkinson's Disease (PD)

Podcast

Anxiety in parkinson's disease and its correlates in mri-based functional connectivity

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Anxiety/Depression
  • Parkinson's Disease (PD)

Podcast

Parkinsonian syndromes and Parkinson's subtypes: Will a single neuroimaging modality ever be enough?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Neuroimaging
  • Parkinson's Disease (PD)

Podcast

Neuroinflammation in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Neurofilament light chain in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Biomarkers
  • Parkinson's Disease (PD)

Podcast

Anti-inflammatory drugs use impacts the risk of developing PD in LRRK2 mutation carriers

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Value of invivosynuclein deposits in Parkinson's disease - Asystematic review and metaanalysis

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Biomarkers
  • Parkinson's Disease (PD)

Podcast

Randomized controlled trial of exercise on objective and subjective sleep in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Exercise
  • Parkinson's Disease (PD)
  • Sleep Disorders

Podcast

Deep brain stimulation for Parkinson, beyond motor improvement: Social and occupational outcomes

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Deep brain stimulation
  • Parkinson's Disease (PD)

Podcast

Late-stage Parkinsonism: Do we know enough?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Antibiotics and Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Fine tuning DBS in Parkinson's disease. How much can we improve?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Deep brain stimulation
  • Parkinson's Disease (PD)

Web article

Mannitol Treatment for Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Parkinson's disease and Lewy body disorders | Congress 2019

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Atypical Parkinsonisms | Congress 2019

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Iron imaging of substantia nigra in Parkinson's disease: A possible biomarker?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Biomarkers
  • Parkinson's Disease (PD)

Podcast

Patient vs. care partner assessment of cognitive disability in Parkinson's: Who's more accurate?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Nutrition-Based Therapy for Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Nutritional Therapy
  • Parkinson's Disease (PD)

Podcast

When should dopaminergic treatment be initiated in Parkinson's disease?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Dopaminergic medications
  • Parkinson's Disease (PD)

Web article

Apathy in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

Advanced therapies for Parkinson's disease: Are they all the same?

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

LRRK2 in Idiopathic Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Podcast

The Mediterranean diet in Parkinson's disease

Listen to episode

Resource Type
  • Podcast
Areas of Interest subtopics
  • Nutritional Therapy
  • Parkinson's Disease (PD)

Web article

Early-stage predictors of Parkinson’s disease evolution – what do we know about REM Sleep Behavior disorder (RBD) and the link to PD?

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)
  • Sleep Disorders

Web article

β2-Adrenoreceptor Agonists and Antagonists and Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Hey Siri, Do I Have Parkinson's?

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Biomarkers in Clinical Practice and Research in Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Biomarkers
  • Parkinson's Disease (PD)

Web article

Multisensory Hallucinations and Delusions in Parkinson’s Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Dance for Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)
  • Physical Therapy/Physiotherapy

Web article

The Relationship Between Diabetes and Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Fatigue in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Autonomic Issues in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Cognitive Problems in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Immunotherapies in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

What Do Single Gene Mutations Really Tell Us About What Goes Wrong in Idiopathic PD?

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

Web article

Inflammation in Parkinson's Disease

Read the article

Resource Type
  • Web article
Areas of Interest subtopics
  • Parkinson's Disease (PD)

World Parkinson's Day, April 11

Learn more »

Become a Member

Education: PD and Parkinsonisms

 

Fundamentals Courses: Parkinson's Disease

MDS offers several on-demand overview courses about a variety of key Parkinson's disease topics, including diagnosis, assessment, cognition, etiology and more.

View courses »

Fundamentals Course: Tauopathies- PSP and CBD

This e-learning module provides an overview and description of the clinical features, diagnosis, pathophysiology and management of progressive supranuclear palsy and corticobasal degeneration.

Course details »

 

Upcoming Courses

Please wait while we gather your results.

Research Tools: PD and Parkinsonism

 

Please wait while we gather your results.

Clinical Outcome Assessments

MDS-owned clinical outcome assessments, translated rating scales, and a listing of other recommended tools.

Read More...

Prodromal PD Calculator

A web-based medical calculator for Prodromal Risk in Parkinsonism. ✪ MEMBERS ONLY

Read More...

MDSGene Tool

MDSGene

Overview of published data on causative gene mutations. ✪ MEMBERS ONLY

Read More...

Video Library

Browse an archive of nearly 2,000 case videos and other multimedia. ✪ MEMBERS ONLY

Read More...


 

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice